This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Life Science Partnering, Investment & Strategy
search

Who will be the next winners in oncology?

Posted by on 20 November 2026
Share this article

Could cancer vaccines move into earlier disease? Will in vivo CAR-T make a difference in solid tumours? And will obesity displace oncology as pharma’s biggest investment priority? Those were among the questions Linda Pullan, of Pullan Consulting, put on the agenda for a panel with Anja Bitterwolf of Debiopharm, Matthias Alder of SRTD Biotech, Lene Gerlach of Women in Life Science Denmark and Hadean Ventures, and Alan Rigby of Epitopea.

Where can radioligand therapies go next?

Targets beyond PSMA and SSTR2 could open up new indications for radioligand therapies. One example is fibroblast activation protein (FAP), a target in the tumour microenvironment being explored across multiple solid tumours. Anja Bitterwolf highlighted smaller targeting molecules designed to penetrate tumours quickly, stay there longer and clear healthy tissue faster. Developers also have a wider choice of alpha- and beta-emitting radioisotopes, making it important to match the isotope to the target biology.

The commercial question is whether developers can reliably get a short-lived product to patients at scale. Anja Bitterwolf singled out isotope supply as a capability to look for in a partner. Pharma is investing in the infrastructure too. Novartis, for example, has announced plans for a fourth US radioligand therapy manufacturing site.

Linda Pullan’s question about tumour heterogeneity matters here. If a target is unevenly expressed within or between tumours, how can developers identify the patients most likely to benefit?

Can cancer vaccines move into earlier disease?

At ESMO, Moderna and Merck reported that adding the personalised mRNA vaccine intismeran autogene to pembrolizumab reduced the relative risk of recurrence or death by 42% compared with pembrolizumab alone in a Phase 3 trial in completely resected stage IIB–IV melanoma. In a much smaller Phase 1 study of BioNTech and Genentech’s investigational vaccine in resected pancreatic cancer, patients who mounted a vaccine-induced T-cell response had longer recurrence-free survival than those who did not. The pancreatic data show an association in 16 patients, and the melanoma result gives a stronger basis for testing the approach after surgery in other cancers.

Matthias Alder sees vaccines playing a role alongside other treatments. Alan Rigby pointed to two reasons some earlier cancer vaccines fell short. Many were tested as a last resort in patients with advanced disease whose immune systems were too compromised to mount the intended response. He also questioned the choice of targets. Some vaccines targeted self-antigens, which are also found in healthy tissue, making it difficult to elicit a strong immune response against the tumour.

Could in vivo CAR-T change cell therapy for solid tumours?

Lene Gerlach pointed to the appeal of generating CAR-T cells inside the body, which could reduce the wait for patient-specific manufacturing. Six acquisitions by five pharma companies between March 2025 and April 2026 had a combined announced value of approximately $14.4 billion, including contingent payments. Lilly’s acquisition of Kelonia Therapeutics accounted for up to $7 billion, including $3.25 billion upfront. The in vivo pipeline is expanding into solid tumours, where clinical validation remains limited. The size of this deal, while Kelonia’s lead programme was still in Phase 1 for multiple myeloma, highlights pharma’s appetite for early-stage deals in in vivo CAR-T.

Ex vivo approaches offer two very different examples of progress. In CARTITUDE-1, 32 of 97 heavily pretreated patients with relapsed or refractory multiple myeloma remained progression-free for at least five years after a single infusion of Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy CARVYKTI, without maintenance or subsequent anti-myeloma therapy. In solid tumours, Immatics reported a 60% objective response rate and a 55% confirmed response rate in a 20-patient Phase 1 subgroup with heavily pretreated ovarian or uterine cancer given clinically relevant doses of its PRAME-targeting TCR-T therapy. That early signal is worth following as the durability data mature.

What can the dark genome offer cancer drug developers?

Alan Rigby described the dark genome as largely quiet in healthy tissue and as a “master regulator” in disease. He pointed to a recent Nature Reviews Cancer Perspective that discusses how tumour cells can display peptides from these overlooked regions and how some of those peptides can be recognised by CD8 T cells. The authors cite Epitopea as an example of industry work on these targets.

Alan Rigby said that the tumour antigens, known as CryptigensTM, Epitopea has identified can elicit an immune response and that some are shared across patients with the same tumour type. That sharing is what makes it possible to develop an off-the-shelf mRNA vaccine for a group of patients. On the morning of the panel, Epitopea announced that the first patient had been dosed in OVACT, its Phase 1/1b study of CryptiVax-1001TM in advanced high-grade serous ovarian cancer. The study will assess safety, tolerability and immune responses. Whether vaccination can delay recurrence is a question for later trials.

The move into clinical trials also brings up a practical question. When eligibility depends on a biomarker or treatment history, could AI help match patients to studies? Trial matching is one possible application of AI beyond drug discovery, a topic Linda Pullan raised with Anja Bitterwolf.

Will early-stage funding get easier, and could obesity displace oncology?

Linda Pullan asked whether the pattern of fewer, larger cheques would change for companies raising seed or Series A funding. That raises a related question for founders. What evidence will get an investor to commit to an oncology programme when large pharma has another major growth area competing for attention?

Deloitte forecasts that obesity will account for 25% of late-stage pipeline sales across 20 leading biopharma companies, ahead of oncology at 20%. The report says obesity’s rise is driven “almost exclusively by GLP-1/GIP assets”. That said, there is no doubt oncology will remain at the forefront of drug development because so many cancers are still life-threatening and patients urgently need treatments that help them live longer.

What do China’s rise and US drug pricing mean for European biotechs?

Lene Gerlach traced China’s rise to more than a decade of strategic investment, regulatory reform and ecosystem development. Alan Rigby highlighted the depth of scientific talent and the pace at which companies compete for assets. One industry estimate puts China at roughly 31% of the global drug development pipeline. J.P. Morgan found that China-origin assets accounted for half of large-cap pharma licensing deals with upfront payments of at least $50 million in Q1 2026. For European biotechs, that means more competition for deals and a wider pool of potential partners. Lene Gerlach also called for more European pension capital to flow into venture funds.

Let’s not forget that China's growing oncology pipeline could also give patients more treatment options, both in China and internationally. Licensing partnerships can help bring medicines developed in China into trials in more countries and, if approved, make them available to patients in those markets.

Linda Pullan also raised US most-favoured-nation drug pricing. For a European biotech, the question is how changes in US pricing could affect a potential partner’s valuation and decisions about where to launch first.

A telling exchange came at the end. Lene Gerlach noted how much a better safety profile or fewer trips to hospital can matter. Alan Rigby challenged the industry to deliver on what it promises people with cancer about survival and quality of life. Anja Bitterwolf asked whether an asset that looks distinctive today will still offer something meaningfully different by the time it reaches patients. Taken together, those points suggest a test for new treatments. Can they help people live longer or better, and can patients get them when they need them?


Share this article

Sign up for Partnering, Investment & Strategy email updates

keyboard_arrow_down